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Abstract
Rett syndrome (RTT) is a genetic disorder characterized by a range of features including cognitive impairment, gait
abnormalities and a reduction in purposeful hand skills. Mice harbouring knockout mutations in the Mecp2 gene display
many RTT-like characteristics and are central to efforts to find novel therapies for the disorder. As hand stereotypies and gait
abnormalities constitute major diagnostic criteria in RTT, it is clear that motor and gait-related phenotypes will be of
importance in assessing preclinical therapeutic outcomes. We therefore aimed to assess gait properties over the prodromal
phase in a functional knockout mouse model of RTT. In male Mecp2 knockout mice, we observed alterations in stride,
coordination and balance parameters at 4 weeks of age, before the onset of other overt phenotypic changes as revealed by
observational scoring. These data suggest that gait measures may be used as a robust and early marker of MeCP2-
dysfunction in future preclinical therapeutic studies.
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Introduction
Rett Syndrome (RTT) is an X-linked disorder caused by loss-of-
function mutations in the MECP2 gene [1] and affecting ,1 in
10,000 females. The RTT phenotype is characterised by a
constellation of typical and associated features [2], most of which
involve brain dysfunction, with notable characteristic features
being developmental regression, loss of motor and language skills
and stereotyped movements of the hands. Gait abnormalities and
motor dysfunction are among the main criteria for diagnosis of
Rett Syndrome [2]. Subsequent to the regression phase, most
RTT patients gain or regain only modest locomotor skills, most
being confined to wheelchairs or requiring lifelong assistance with
walking. Gait has been analysed in mobile RTT patients post-
regression and has been reported to be wide-based and clumsy [3].
Many of the features of RTT are successfully modelled in Mecp2
knockout mice, and locomotor behaviour has been shown to be
affected [4–7]. Although RTT has commonly been thought to be
neurodevelopmental in character, recent work has demonstrated
that the phenotype can be rescued to an appreciable extent by
restoration of Mecp2 gene function at any stage postnatally [7,8]
whilst adult inactivation of Mecp2 results in a RTT-like phenotype
[9,10]. These studies suggest that RTT may potentially be both
preventable and reversible in patients. As more therapeutic
avenues are explored in RTT, the characterisation of good
outcome measures for therapeutic interventions is becoming of
prime importance.
Previous gait-related studies of Mecp2 knockout mice have
utilised either paw inking or video imaging on a static surface
[7,11,12] and have reported significant differences in several gait
parameters in symptomatic animals. However, these approaches
are limited in the range of gait phenotypes that can be
characterised in detail, and did not account for speed differences
between the Mecp2 knockout mice (which have clear motor and
movement deficits) and wild-type controls. Moreover, there is little
data concerning the longitudinal trajectory of the gait-related
phenotype in these mice, which is important for the development
of outcome biomarkers for use in pre-clinical therapeutics studies.
We therefore carried out a thoroughgoing analysis, using a
treadmill apparatus, of the gait-related aspects of phenotype in
Mecp2 knockout mice to inform future studies aimed at developing
accurate and easy to implement outcome measures for pre-clinical
therapeutic strategy testing. Because other variables in these
knockout mice, such as running speed and motivation, could be
confounding in a study of gait, we employed a treadmill, which
allowed us to minimise any such confounding factors. Further-
more, the automated analysis provides an objective method of
calculating gait parameters. We detected a number of novel gait
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parameters affected in knockout mice, several of which were
detectable before the onset of other overt RTT phenotypes.
Methods
Mecp2-stop mice
A breeding colony of Mecp2-stop mice (Mecp2tm2Bird, Jackson
Laboratories Stock No. 006849) was set up using Mecp2stop/+
heterozygous female stock mice (a kind gift from Prof. A. Bird,
University of Edinburgh, UK). The disease-causing mutation in
this RTT model is the insertion of a targeted STOP cassette
upstream of exon 3, which leads to a null product from the mutant
allele and is therefore akin to a gene knockout. All mice used in
experiments were male Mecp2stop/y offspring resulting from a
breeding scheme involving at least ten generations of backcross
from a congenic C57BL/6 background onto a BALB/c back-
ground. Genotype was determined from ear clipping samples by
PCR as described [8]. Mice were maintained on a 12 h light/dark
cycle and provided with food and water ad libitum. Experiments
were carried out in accordance with the European Communities
Council Directive (86/609/EEC) and a project licence and
approval under the UK Scientific Procedures Act (1986). The
work was also approved by the University of Glasgow Ethical
Review Panel.
Phenotype Scoring
From the age of 3 weeks (weaning), mice were scored weekly for
signs of the Mecp2-stop phenotype using an observational severity
score described previously [8,13–15]. Briefly, each of six observ-
able features (mobility, gait, hindlimb clasping, tremor, breathing
and general condition) were scored on a 0–2 scale (0 - no signs, 1 -
mild signs; 2 - severe/obvious signs; see [8] for details), with the
observer blind to genotype. Scores were aggregated to give an
overall severity score out of 12 for each individual mouse.
Gait analysis
Gait was analysed using the DigiGait imaging system (Mouse
Specifics Inc., Boston, MA, USA). A range of running speeds were
tested in a pilot experiment to define a highest speed that all mice
were able to run at, thus excluding differences in self-selected
speeds as the most critical confounding factor in the interpretation
Figure 1. Treadmill-based measurement of gait properties in Mecp2stop/y mice. (A) Video still image showing mouse walking on transparent
treadmill (viewed from below) at 25 cm/s. (B) Placement of each paw is detected from the video illustrated in (A). (C) Graph of paw area in contact
with the treadmill surface for each paw over time (one session, one animal); the area outlined in black has been replotted in (D). (D) Excerpt from (C)
showing calculated paw area in contact with treadmill surface over time for a representative single paw (right fore; pink in B and C), from which
multiple stride indices can be obtained (labeled). (E) Column plots showing stride time measures (mean +/2 SEM) for each limb in 8 week old wild-
type (WT) and Mecp2stop/y mice (***p,0.001 relative to WT; t-test, n = 5 per genotype).
doi:10.1371/journal.pone.0112889.g001
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of over-ground walking subjects. Digital videos of the ventral
surface of the mice were captured as they ran at 25 cm/s (a speed
at which all mice including the Mecp2 knockout mice were able to
steadily run for a minimum of 6 complete strides) on a transparent
motorised treadmill (figure 1A). To ensure mice remained within
the viewing field of the camera they were contained within an
open-bottomed Plexiglas chamber with adjustable bumpers at
either end. Videos captured by the camera were analysed with the
supplied proprietary DigiGait software to produce digitised and
vectorised paw images (figure 1B); this enabled tracking over time
and the production of a waveform pattern representing the
stepping cycles for each paw (figure 1C, D), from which the
DigiGait software calculates numerous gait parameters/indices.
Animals that refused or were unable to perform (in the case of
some Mecp2stop/y mice) were removed from the study.
Statistical analysis
All results are given as mean 6 standard error of the mean
(SEM). Groups were compared using 2-way repeated measures
ANOVA with Tukey post hoc pairwise comparisons, or the Mann
Whitney test, as appropriate (Minitab 16.0, Minitab Inc., USA).
Results
The mutant phenotype trajectory was assessed by weekly
observational scoring from week three onwards. From five weeks
of age Mecp2stop/y animals showed a progressively more severe
phenotype (figure 2A) that was significantly different from that for
WT animals, which scored zero for the duration of the study (p,
0.002 from 5 weeks onwards, Mann Whitney pairwise compar-
isons; we set p,0.01 as our alpha value for significance to control
for multiple testing). Mecp2stop/y mice have reduced survival [8,13]
and consequently the study was restricted to 10 weeks.
Subtle changes in gait parameters precede the onset of
overt RTT-like signs in Mecp2stop/y mice
Treadmill-based gait analysis was used to characterise the gait
of male hemizygous Mecp2stop/y mice at three different time points
after birth, four weeks, eight weeks and ten weeks. Several aspects
of gait were assessed, including stride, coordination and balance
parameters. Stride length, the distance between initial contacts of
the same paw in one complete stride, is a basic gait feature and a
reduction in this parameter is commonly seen in animal models of
human disease with a prominent motor component such as
Parkinson disease [16]. There was a highly significant effect of
genotype on stride length (F1,32 = 63.9, p,0.0001, 2-way repeated
measures ANOVA). No difference was observed between Mecp2-
stop/y and WT animals at four weeks (figure 2B), but there were
highly significant differences between genotypes at both eight
weeks and ten weeks, with Mecp2stop/y animals having a 2261.3%
reduction in stride length compared to WT at 10 weeks (p,0.0001
Tukey post hoc pairwise comparisons).
Gait coordination was assessed through measurement of
parameters including overlap distance, stance width, step angle
and gait symmetry. During normal gait in quadrupeds such as
mice the forelimbs and hindlimbs show a stereotypical pattern of
movement relative to one another. The hindlimbs are typically
swung forwards such that hindpaws are plantar placed during
stance, close to, but often a little ahead of, the position occupied by
the forepaws during the preceding forepaw stance phase. The
hindpaw stride therefore overlaps that of the forepaw stride in the
direction of movement (antero-posterior axis). Injury or disease
can lead to a change in the spatial relationship between forelimb
and hindlimb strides such that the degree of overlap between the
forepaw and subsequent hindpaw stance positions may increase or
decrease. For example in models of cerebellar dysfunction, an
increase in overlap distance (the distance between placement of
front and hind paws) is observed [17]. In the current study,
Mecp2stop/y mice showed much greater overlap distance than WT
mice at all time points (figure 2C, F1,32 = 111.42, p,0.001, 2-way
repeated measures ANOVA with Tukey post hoc pairwise
comparisons), even at four weeks, before an overt phenotype is
observed using the observational scoring system (figure 2A). It is
known that mice with lesions or diseases that affect balance and
postural stability tend to adopt a wider stance, presumably to
compensate for centre of gravity shifts during locomotion. Stance
width (distance between the centre of the two hind paws) was
significantly greater in Mecp2stop/y mice than WT at 4 weeks but
there was no significant difference at 8 and 10 weeks (figure 2D,
F1,32 = 23.79, p,0.001, p,0.01 at 4 weeks, and p.0.05 at 8 and
Figure 2. Automated gait analysis reveals early signs of motor
defects in Mecp2stop/y mice. (A) Plot showing aggregate phenotype
severity score (mean +/2 SEM) in male wild-type (WT, black diamond
symbols) and Mecp2stop/y (grey circles) mice. Mecp2stop/y mice show a
gradual phenotype score progression that is significantly different from
WT (WT n=7; Mecp2stop/y n= 8 at 3–7 weeks, n = 7 at week 8, n = 5 at
week 9 and n=4 at week 10); decreasing numbers of Mecp2stop/y mice
are explained by early death of some mutant mice. (B–F) Plots showing
stride length, overlap distance, stance width, step angle and gait
symmetry (mean +/2 SEM) measured in WT and Mecp2stop/y mice at 4, 8
and 10 weeks (WT n=7 at 4 weeks and 5 at 8 & 10 weeks; Mecp2stop/y
n= 6 at 4 weeks, n = 5 at weeks 8 & 10. The treadmill speed was 25 cm/
s. *p,0.05 **p,0.01 ***p,0.001, Mann Whitney pairwise comparisons
(A) and 2-way repeated measures ANOVA with Tukey post hoc pairwise
comparisons (B–F).
doi:10.1371/journal.pone.0112889.g002
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10 weeks, 2-way repeated measures ANOVA with Tukey post hoc
pairwise comparisons). Step angle records the combined angle
formed by the long axes of the hind paws in relation to the long
axis of the body and reflects changes in paw rotation that are a
measure of spinal dysfunction [18]. Mecp2stop/y animals showed a
significantly lower step angle than WT at all time points
(figure 2E, F1,32 = 43.23, p,0.001, p=0.02 at 4 weeks, and p,
0.01 at 8 and 10 weeks, 2-way repeated measures ANOVA with
Tukey post hoc pairwise comparisons), indicating an inward
rotation of the hind paws in the mutant animals. Other aspects of
brain and spinal pathway-based motor coordination were assessed
using the gait symmetry parameter, which measures how often
strides are taken by the hindpaws relative to the forepaws. In
normal gait there will be one forepaw step for every hind paw step
taken. There was no difference in gait symmetry observed between
the genotypes (figure 2F).
Discussion
In this study, we used a treadmill system to investigate potential
gait abnormalities in a mouse model of Rett syndrome. We aimed
to characterize the onset and progression of gait phenotypes and
also to evaluate whether gait abnormalities provide rapid, robust
and objective outcome measures that might be utilized in future
studies to assess the effectiveness of therapeutic interventions. We
found that Mecp2stop/y mice showed several highly significant gait
alterations including increased stride frequency, less precise paw
placement and a wider gait. Gait abnormalities and gait
dysfunction are key diagnostic characteristics of RTT in girls
and these features represent prominent and disabling aspects of
the disorder [2,19–21]. Mecp2 knockout mice have been reported
previously to display gait abnormalities at the age of 5–8 weeks
[7,11,12], and our findings agree with these reports. However, our
findings reveal locomotor deficits in these mice across a wide range
of gait domains including stride features and coordination, and
that these deficits are evident from 4 weeks of age in theMecp2stop/y
model and are maintained over early adult life in many cases.
Early detection of biomarkers of the phenotype is potentially
important in preclinical therapeutic studies. At 4 weeks of age,
hemizygous Mecp2 knockout mice are typically considered to be
‘presymptomatic’ for overt Rett-like signs [4,5,8]. Certain cellular
and network features of MeCP2-deficiency, such as imbalance
between cortical excitatory and inhibitory circuits, are apparent in
Mecp22/y mice from as early as 4–5 weeks [22], but many other
features, such as diminished synaptic plasticity [13,23] and the
appearance of reduced locomotion, seizures and abnormal
breathing, are typically reported to occur later in male Mecp2
knockout mice [24].
Whilst RTT predominantly affects females, male knockout mice
are typically used for RTT preclinical studies, in part to overcome
the complexities resulting from mosaic expression of Mecp2 in
heterozygous females (due to X chromosome inactivation) but also
because the course of phenotype development is more aggressive,
more stereotyped and less variable in the males, and they therefore
provide a more useful and experimentally tractable test-bed for
putative therapeutic interventions [25].
The treadmill-based gait analysis used here has been validated
in a variety of disease models including amyotrophic lateral
sclerosis [26], Parkinson disease [27,28] and Huntington disease
[29,30] and has been shown to be a simple, sensitive and objective
method for detecting gait abnormalities. We have shown here that
certain gait abnormalities can be detected very early in the disease
progression in the RTT model used here, and we would argue that
these measures should be evaluated as biomarkers for early and
deep-seated aspects of the RTT-like phenotype, with a view to
developing them as early indicators of amelioration and/or
reversibility of RTT-like phenotypes in preclinical therapeutic
studies [31–35].
Acknowledgments
We are grateful to the Rett Syndrome Association Scotland, Chief Scientist
Office and the Rett Syndrome Research Trust for support.
Author Contributions
Conceived and designed the experiments: SC MB KG. Performed the
experiments: KG PR. Analyzed the data: KG PR JR. Wrote the paper: SC
PR KG MB.
References
1. Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U, et al. (1999) Rett
syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-
binding protein 2. Nat Genet 23: 185–188.
2. Neul JL, Kaufmann WE, Glaze DG, Christodoulou J, Clarke AJ, et al. (2010)
Rett syndrome: revised diagnostic criteria and nomenclature. Ann Neurol 68:
944–950.
3. Naidu S, Murphy M, Moser HW, Rett A (1986) Rett syndrome–natural history
in 70 cases. American journal of medical genetics Supplement 1: 61–72.
4. Chen RZ, Akbarian S, Tudor M, Jaenisch R (2001) Deficiency of methyl-CpG
binding protein-2 in CNS neurons results in a Rett-like phenotype in mice. Nat
Genet 27: 327–331.
5. Guy J, Hendrich B, Holmes M, Martin JE, Bird A (2001) A mouse Mecp2-null
mutation causes neurological symptoms that mimic Rett syndrome. Nat Genet
27: 322–326.
6. Shahbazian M, Young J, Yuva-Paylor L, Spencer C, Antalffy B, et al. (2002)
Mice with truncated MeCP2 recapitulate many Rett syndrome features and
display hyperacetylation of histone H3. Neuron 35: 243–254.
7. Robinson L, Guy J, McKay L, Brockett E, Spike RC, et al. (2012)
Morphological and functional reversal of phenotypes in a mouse model of Rett
syndrome. Brain: a journal of neurology 135: 2699–2710.
8. Guy J, Gan J, Selfridge J, Cobb S, Bird A (2007) Reversal of neurological defects
in a mouse model of Rett syndrome. Science 315: 1143–1147.
9. McGraw CM, Samaco RC, Zoghbi HY (2011) Adult neural function requires
MeCP2. Science 333: 186.
10. Cheval H, Guy J, Merusi C, De Sousa D, Selfridge J, et al. (2012) Postnatal
inactivation reveals enhanced requirement for MeCP2 at distinct age windows.
Human molecular genetics 21: 3806–3814.
11. Kerr B, Silva PA, Walz K, Young JI (2010) Unconventional transcriptional
response to environmental enrichment in a mouse model of Rett syndrome.
PLoS One 5: e11534.
12. Santos M, Summavielle T, Teixeira-Castro A, Silva-Fernandes A, Duarte-Silva
S, et al. (2010) Monoamine deficits in the brain of methyl-CpG binding protein 2
null mice suggest the involvement of the cerebral cortex in early stages of Rett
syndrome. Neuroscience 170: 453–467.
13. Weng SM, McLeod F, Bailey ME, Cobb SR (2011) Synaptic plasticity deficits in
an experimental model of Rett syndrome: long term potentiation saturation and
its pharmacological reversal. Neuroscience 180: 314–321.
14. Derecki NC, Cronk JC, Lu Z, Xu E, Abbott SB, et al. (2012) Wild-type
microglia arrest pathology in a mouse model of Rett syndrome. Nature 484:
105–109.
15. Lioy DT, Garg SK, Monaghan CE, Raber J, Foust KD, et al. (2011) A role for
glia in the progression of Rett’s syndrome. Nature 475: 497–500.
16. Fernagut PO, Diguet E, Labattu B, Tison F (2002) A simple method to measure
stride length as an index of nigrostriatal dysfunction in mice. Journal of
neuroscience methods 113: 123–130.
17. Johnson EM, Craig ET, Yeh HH (2007) TrkB is necessary for pruning at the
climbing fibre-Purkinje cell synapse in the developing murine cerebellum. The
Journal of physiology 582: 629–646.
18. Basso DM, Beattie MS, Bresnahan JC (2002) Descending systems contributing
to locomotor recovery after mild or moderate spinal cord injury in rats:
experimental evidence and a review of literature. Restorative neurology and
neuroscience 20: 189–218.
19. Hagberg B, Witt-Engerstrom I (1986) Rett syndrome: a suggested staging system
for describing impairment profile with increasing age towards adolescence.
American journal of medical genetics Supplement 1: 47–59.
20. Nomura Y, Segawa M (1992) Motor symptoms of the Rett syndrome: abnormal
muscle tone, posture, locomotion and stereotyped movement. Brain Dev 14
Suppl: S21–28.
21. Nomura Y, Segawa M (1990) Characteristics of motor disturbances of the Rett
syndrome. Brain & development 12: 27–30.
Gait Analysis in Mecp2 Knockout Mice
PLOS ONE | www.plosone.org 4 November 2014 | Volume 9 | Issue 11 | e112889
22. Dani VS, Chang Q, Maffei A, Turrigiano GG, Jaenisch R, et al. (2005) Reduced
cortical activity due to a shift in the balance between excitation and inhibition in
a mouse model of Rett syndrome. Proc Natl Acad Sci U S A 102: 12560–12565.
23. Asaka Y, Jugloff DG, Zhang L, Eubanks JH, Fitzsimonds RM (2006)
Hippocampal synaptic plasticity is impaired in the Mecp2-null mouse model
of Rett syndrome. Neurobiol Dis 21: 217–227.
24. Stearns NA, Schaevitz LR, Bowling H, Nag N, Berger UV, et al. (2007)
Behavioral and anatomical abnormalities in Mecp2 mutant mice: a model for
Rett syndrome. Neuroscience 146: 907–921.
25. Katz DM, Berger-Sweeney JE, Eubanks JH, Justice MJ, Neul JL, et al. (2012)
Preclinical research in Rett syndrome: setting the foundation for translational
success. Disease models & mechanisms 5: 733–745.
26. Wooley CM, Sher RB, Kale A, Frankel WN, Cox GA, et al. (2005) Gait analysis
detects early changes in transgenic SOD1(G93A) mice. Muscle & nerve 32:
43–50.
27. Domanskyi A, Geissler C, Vinnikov IA, Alter H, Schober A, et al. (2011) Pten
ablation in adult dopaminergic neurons is neuroprotective in Parkinson’s disease
models. FASEB journal: official publication of the Federation of American
Societies for Experimental Biology 25: 2898–2910.
28. Glajch KE, Fleming SM, Surmeier DJ, Osten P (2012) Sensorimotor assessment
of the unilateral 6-hydroxydopamine mouse model of Parkinson’s disease.
Behavioural brain research 230: 309–316.
29. Amende I, Kale A, McCue S, Glazier S, Morgan JP, et al. (2005) Gait dynamics
in mouse models of Parkinson’s disease and Huntington’s disease. Journal of
neuroengineering and rehabilitation 2: 20.
30. Carter RJ, Lione LA, Humby T, Mangiarini L, Mahal A, et al. (1999)
Characterization of progressive motor deficits in mice transgenic for the human
Huntington’s disease mutation. The Journal of neuroscience: the official journal
of the Society for Neuroscience 19: 3248–3257.
31. Weng SM, McLeod F, Bailey ME, Cobb SR (2011) Synaptic plasticity deficits in
an experimental model of rett syndrome: long-term potentiation saturation and
its pharmacological reversal. Neuroscience 180: 314–321.
32. Asaka Y, Jugloff DG, Zhang L, Eubanks JH, Fitzsimonds RM (2006)
Hippocampal synaptic plasticity is impaired in the Mecp2-null mouse model
of Rett syndrome. Neurobiology of disease 21: 217–227.
33. Gadalla KK, Bailey ME, Cobb SR (2011) MeCP2 and Rett syndrome:
reversibility and potential avenues for therapy. The Biochemical journal 439:
1–14.
34. Gadalla KK, Bailey ME, Spike RC, Ross PD, Woodard KT, et al. (2013)
Improved survival and reduced phenotypic severity following AAV9/MECP2
gene transfer to neonatal and juvenile male Mecp2 knockout mice. Mol Ther 21:
18–30.
35. Garg SK, Lioy DT, Cheval H, McGann JC, Bissonnette JM, et al. (2013)
Systemic delivery of MeCP2 rescues behavioral and cellular deficits in female
mouse models of Rett syndrome. J Neurosci 33: 13612–13620.
Gait Analysis in Mecp2 Knockout Mice
PLOS ONE | www.plosone.org 5 November 2014 | Volume 9 | Issue 11 | e112889
